SAG
ALNY icon

Susquehanna Advisors Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Susquehanna Advisors Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-286,100
Closed -$130M – 170
2025
Q3 		$130M Buy
+286,100
New +$117M 2% 16

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Susquehanna Advisors Group's ALNY Position: Q4 2025 in Review

Susquehanna Advisors Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 286,100 shares — an estimated $130M sold.

Susquehanna Advisors Group first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $130M in Q3 2025. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Susquehanna Advisors Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Susquehanna Advisors Group sold 286,100 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $130M.
  • Susquehanna Advisors Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Susquehanna Advisors Group's Alnylam Pharmaceuticals position peaked at $130M in Q3 2025.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Susquehanna Advisors Group's 13F filing for Q4 2025, filed 17 Feb 2026.